MedTrace Logo

Acute Glycemic and Insulinemic Response of FOSSENCE™

NCT03755232 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-09-11

No results posted yet for this study

Summary

Short chain fructooligosaccharide (FOS) is known as a prebiotic fiber/nutrient and has been documented to demonstrate different health benefits including glucose control, gut health, mineral absorption, weight and immunity.

FossenceTM is a short chain fructo-oligosaccharide (scFOS), sweet tasting, soluble prebiotic dietary fibre which is produced through Tata Chemicals Limited's patented process and is currently US GRAS notified (safe for consumption). The formulation and properties of scFOS suggest that the molecule may potentially play a role in glucose and insulin metabolism.

The purpose of this study is to explore the rise of glucose and insulin in the blood after consuming FossenceTM that has been added or substituted into a sugar drink or white bread.

Conditions

  • Dietary Modification
  • Healthy

Interventions

DIETARY_SUPPLEMENT

scFOS

Fossence™ (short chain Fructo-oligosaccharides (scFOS)

OTHER

Control

water or dextrose or white bread

Sponsors & Collaborators

  • Glycemic Index Laboratories, Inc

    collaborator INDUSTRY

  • TATA CHEMICALS LTD

    lead INDUSTRY

Principal Investigators

  • Thomas MS Wolever, MD · Glycemic Index Laboratories, Inc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-06
Primary Completion
2019-02-27
Completion
2019-09-09

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03755232 on ClinicalTrials.gov